Investigation in Progress — No Complaint Filed Yet
BG&G is actively investigating potential securities fraud claims against Theravance Biopharma, Inc.. If a complaint is filed, this page will be updated. Investors are encouraged to contact us now to preserve their rights.
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Theravance Biopharma, Inc. (“Theravance” or “the Company”) (NASDAQ: TBPH). Investors who purchased Theravance securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Theravance has violated federal securities laws.
Theravance Investigation Details
On March 3, 2026, Theravance reported spending millions of dollars on operations expenses while its CYPRESS trial was in the enrollment phase, representing a major cash burn on a high-risk program. The Company’s trial ultimately failed.
What’s Next for Theravance Investors?
If you are aware of any facts relating to this investigation or purchased Theravance securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911
TBPH — Stock Performance
About Bronstein, Gewirtz & Grossman, LLC
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”